Key Takeaways

  • Zepbound® and retatrutide both target weight loss, but through different mechanisms. Zepbound® is a dual agonist (GLP-1 and GIP), while retatrutide is a triple agonist that adds glucagon.
  • Only Zepbound® is FDA-approved and available today. Retatrutide shows promising early results but remains investigational, with a possible submission for approval in early 2027.
  • Early data suggests retatrutide may produce greater weight loss, but it's not yet confirmed. Phase 2 and ongoing Phase 3 trials show strong results, though the TRIUMPH program is still underway.

In August 2026, Eli Lilly sued six U.S. companies for selling black market retatrutide, a weight loss medication that’s still going through the FDA approval process. The FDA warned that these companies are breaking the law by selling products that haven’t cleared official safety, effectiveness, and quality standards.

The fact that six companies are illegally selling retatrutide demonstrates a real demand for this medication. Retatrutide has gained widespread attention because it builds on the success of Zepbound®, one of the most effective weight loss medications on the market. Zepbound® (tirzepatide) uses a dual-action formula, targeting glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Retatrutide adds a third hormone target, glucagon, which is showing even more promising results in clinical trials.

So, is retatrutide worth waiting for? To help you decide, we’ll compare Zepbound® versus retatrutide and explore what the research shows about both.

‍

How do Zepbound® and retatrutide work?

Zepbound®’s active ingredient is called tirzepatide. An “active ingredient” is the part of the drug mainly responsible for its desired effect—in this case, weight loss. Tirzepatide is a dual agonist, which means it mimics two hormones the body naturally produces: 

  • Glucagon-like peptide-1 (GLP-1) is an incretin hormone, meaning it prompts the pancreas to release insulin and regulate blood sugar levels. The hormone also slows how quickly food leaves the stomach and suppresses appetite.
  • Glucose-dependent insulinotropic polypeptide (GIP) is another incretin hormone, but it’s more closely associated with how the body uses and stores fat. 

Retatrutide is a triple agonist. It targets GLP-1 and GIP, plus a third: glucagon. Glucagon is a hormone that the pancreas produces. Its main job is to regulate blood sugar levels. It does this by telling your liver to release stored glucose when levels run low. Glucagon also plays a role in how the body breaks down and burns stored fat. 

‍

Retatrutide vs. Zepbound® comparison

While these medications both encourage weight loss, they have a few key differences:

Zepbound® (tirzepatide) Retatrutide
Manufacturer Eli Lilly Eli Lilly
How it works Mimics GLP-1 and GIP Mimics GLP-1, GIP, and glucagon
Weight loss effectiveness Patients lose approximately 21% body weight over 72 weeks at 15 mg, on average (SURMOUNT-1) Patients lose an average of approximately 24% body weight over 48 weeks (phase 2 trial findings)
Cost Direct pay ranges from $299 to $699; costs vary with insurance Not publicly available
Side effects Mild-to-moderate gastrointestinal (GI) side effects like nausea and vomiting are most common Its safety profile is still being studied
Availability Widely available at U.S. pharmacies and via LillyDirect (Eli Lilly’s direct-to-consumer platform) Not publicly available
FDA-approved indication Chronic weight management; moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity None (still investigational)

‍

Zepbound® (tirzepatide) vs. retatrutide weight loss comparison: What does clinical research show?

Let’s explore and compare what the evidence says about Zepbound® (tirzepatide) and retatrutide.

SURMOUNT-1

SURMOUNT-1, a phase 3 trial published in the New England Journal of Medicine in 2022, looked at tirzepatide’s safety and efficacy for weight loss. It enrolled 2,539 adults who had obesity or were overweight with a weight-related condition. None had diabetes. 

Over 72 weeks, participants took one of three tirzepatide doses: 5 mg, 10 mg, or 15 mg—or a placebo. Those on the 15 mg dose lost an average of approximately 21% of their body weight. This is a meaningful jump from the placebo group, who lost 3% on average. 

Outcomes on other doses were meaningful, too. The 5 mg group lost an average of 15%, while the 10 mg group lost an average of 19.5%. Approximately nine in 10 participants taking tirzepatide lost 5% or more of their body weight. 

Beyond numbers on the scale, researchers also looked at:

  • Cardiometabolic health: Tirzepatide improved several markers linked to metabolic and heart health compared with placebo, including waist circumference, blood pressure, and fasting insulin.
  • Prediabetes reversion: About 40% of participants had prediabetes when the trial began. Prediabetes is when blood sugar levels are higher than normal, but not high enough for a type 2 diabetes diagnosis. By week 72 of the trial, blood sugar levels of a large majority (over 95%) normalized. 

SURMOUNT post hoc analysis 

Researchers conducted a post hoc analysis of the SURMOUNT clinical development program (SURMOUNT-1 is one study in this program). One group published their findings in Obesity, which is the journal of The Obesity Society. They highlighted how some tirzepatide participants self-reported real gains in physical function. This refers to the ability to perform everyday activities, such as walking and climbing stairs. Participants who began the study with physical limitations reported the most meaningful progress. 

Another group published their findings in Diabetes, Obesity and Metabolism. They asked, “What kind of weight loss did tirzepatide support?” They found approximately three-quarters of tirzepatide-driven weight loss stemmed from fat (74%). Lean mass made up the rest (26%), which includes muscle. 

Losing some lean mass is normal. Researchers noted that tirzepatide didn’t produce disproportionate lean mass loss. They did, however, emphasize how lifestyle changes, like diet and exercise, played a role. That’s why it’s important to have a care team that looks beyond numbers on the scale. 

TRIUMPH program

Retatrutide is earlier in its journey. In a 2023 phase 2 trial, also published in the New England Journal of Medicine, researchers followed 338 adults with obesity or overweight with a weight-related condition. None had diabetes. Over 48 weeks, participants on the highest dose (12 mg) lost an average of approximately 24% of their body weight. Those on placebo lost approximately 2%. 

Retatrutide has since moved into phase 3, a larger set of trials called the TRIUMPH program. In December 2025, TRIUMPH-4 reported meaningful weight loss outcomes for adults with obesity and knee osteoarthritis. Those on the highest dose (12 mg) of retatrutide lost an average of approximately 29% of their body weight over 68 weeks. Many reported less knee pain, too. TRIUMPH-1 (May 2026), a larger-scale trial of over 2,300 participants, reported average weight losses of up to approximately 28% over 80 weeks. 

Although promising, it’s worth keeping these outcomes in perspective: the TRIUMPH program is ongoing. We can’t make concrete conclusions yet. 

As of July 2026, TRIUMPH-5 is underway. It’s a head-to-head trial comparing tirzepatide and retatrutide in adults with obesity. No early outcomes have been released just yet. Its estimated completion date is December 2026, with insights following soon after. 

Retatrutide versus tirzepatide: Which is better?

Although promising, it’s worth keeping these outcomes in perspective: the TRIUMPH program is ongoing. We can’t make concrete conclusions yet. 

As of July 2026, TRIUMPH-5 is underway. It’s a head-to-head trial comparing tirzepatide and retatrutide in adults with obesity. No early outcomes have been released just yet. Its estimated completion date is December 2026, with insights following soon after.

Maven Consumer

Not sure which GLP-1 medication to choose?

Maven makes it easy to connect with a specialist who can walk you through your options and match you with the right GLP-1 medication for your goals.

Explore GLP-1 Care

What are the side effects of Zepbound® and retatrutide?

Because retatrutide is still moving through the FDA approval process, it doesn’t have an official commercial label yet. So far, clinical trials show that its side effects closely mirror approved GLP-1 medications. 

Both Zepbound® and retatrutide’s most frequent side effects impact the digestive system. These medications slow how quickly food leaves your stomach and moves through your intestines, which can trigger nausea, vomiting, diarrhea, and constipation. Side effects typically peak when you start or escalate doses, then ease as your body adjusts. 

Retatrutide may also cause unusual skin sensations like tingling or burning (dysesthesia). While Zepbound®’s label lists dysesthesia as an uncommon side effect, roughly one in eight participants on higher doses of retatrutide reported it in the TRIUMPH-1 trial. 

Serious risks associated with Zepbound®

Zepbound®’s FDA-approved label outlines several less common but more serious risks:

  • Thyroid tumors: Tirzepatide caused thyroid tumors in animal studies involving rats. Recent reviews of human clinical data haven’t shown a matching increase in thyroid cancer risk among patients. However, Zepbound® still carries a boxed warning for thyroid C-cell tumors. You shouldn’t take Zepbound® if you or a family member has had medullary thyroid cancer (MTC), or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2).
  • Gallbladder problems: Rapid weight loss can prompt the liver to release extra cholesterol into bile. It might also prevent the gallbladder from emptying properly, so bile stays in the organ longer. Both issues increase the risk of gallstones.
  • Pancreatitis: This inflammation of the pancreas causes severe belly pain that can spread to the back, sometimes accompanied by nausea or vomiting. Researchers believe gallstones or bile sludge is the most likely trigger, as they can block the shared ducts draining the gallbladder and pancreas.
  • Gastroparesis: Because Zepbound® slows digestion, its label advises against use if you already have severe gastroparesis, a condition where stomach emptying is already delayed.
  • Low blood sugar (hypoglycemia): Zepbound® might decrease blood sugar below safe levels. The risk rises if you take it alongside insulin or a sulfonylureas, a class of diabetes medications.

Serious risks associated with retatrutide

Since retatrutide doesn’t have a label yet, it also doesn’t list any boxed warnings. But many approved GLP-1 formulations aren’t ideal for people with a personal or family history of MTC, MEN 2, or pancreatitis. As a precaution, researchers running phase 3 retatrutide trials have excluded these groups from participating.

‍

How much do Zepbound® and retatrutide cost?

Zepbound®’s list price is $1,087 a month, but several options can significantly reduce what you pay:

  • Commercial insurance: If your plan covers Zepbound®, Eli Lilly’s savings card can lower the cost of the single-dose pen to as little as $25 for a one to three-month supply, subject to monthly and yearly limits.
  • Out-of-pocket payment: If you lack insurance or your plan excludes weight loss medications, you can purchase Zepbound® from LilyDirect. Out-of-pocket costs typically range from $299 to $699 per month, depending on your dosage and refill timing.
  • Medicare: Through the temporary Medicare GLP-1 Bridge Program, running through December 2027, eligible Medicare Part D members might have access to the Zepbound® KwikPen for a flat copay of pay $50 per month. Having Medicare Part D coverage doesn’t automatically mean you’ll qualify, though. If you received a GLP-1 through Part D during 2026 or have certain conditions that Part D already covers, you’ll likely be excluded from the Bridge Program. 

What about retatrutide?

Retatrutide’s retail price remains unknown while it moves through the FDA approval process. Some online vendors sell products that claim to contain retatrutide, labeled “for research purposes” or “not for human consumption.” However, the FDA strongly advises against buying these products, as the agency hasn’t reviewed their safety and quality, and they could be harmful.

‍

Should you wait for retatrutide or start Zepbound® now?

Retatrutide remains unavailable outside of clinical trials. Eli Lilly is finalizing its Chemistry, Manufacturing, and Controls (CMC) data package, a requirement for federal review. The company plans to submit retatrutide for U.S. approval in 2027 under a Biologics License Application (BLA). However, the FDA has declined to classify retatrutide as a biologic, and Eli Lilly is challenging that position in court. How this legal dispute resolves could influence the review timeline.

Once Eli Lilly officially submits its application, which usually takes about two months, standard FDA review typically takes six to 10 months, depending on whether the agency grants priority review. That places potential approval in late 2027 at the earliest, and the classification debate could extend that wait. Even after approval, individual insurance coverage and savings program availability remain uncertain.

In the meantime, Zepbound® is available today and remains one of the most effective weight-loss medications on the market. The FDA also approved Wegovy® HD, a higher dose semaglutide formulation, in March 2026. Currently, there’s no trial comparing all three medications, so the retatrutide versus tirzepatide versus semaglutide question remains open.

Starting tirzepatide treatment now doesn’t lock you in, either. If retatrutide gains approval, you and your clinician can decide whether switching from tirzepatide to retatrutide makes sense for you.

‍

Navigating GLP-1 care with Maven Clinic

Zepbound® and retatrutide are both solid options, depending on what final trials say about retatrutide. Our specialists at Maven Clinic can help you decide on your next move. As specialists in both GLP-1 and women’s care, we guide you on the right path for your body, supporting sustainable long-term outcomes. 

‍Discover our approach to GLP-1 care.

"There's so much noise online, and I wanted someone I could actually trust. With Maven, I understood my options, why I was taking what I was taking, and what to expect before I ever started. It felt clear from day one."
Sarah
"I tried a GLP-1 through another service first. Got the prescription, got nothing else. I'm in my late 40s, my body was changing, and I was asking AI my follow-up questions. Maven was the first time I had a clinician who knew what was going on with me and helped me feel like me again."
Priya
"My clinician covered things I hadn't thought to ask, like how GLP-1s can affect birth control. I felt like I was making an informed decision instead of just following a trend."
Diane

FAQ

What’s the difference between retatrutide and tirzepatide?
Is retatrutide more effective than Zepbound® for weight loss?
When will retatrutide be FDA-approved?
Can you switch from Zepbound® to retatrutide once it's approved?
Is retatrutide a GLP-3?
What are retatrutide’s benefits?
What else is retatrutide being studied for besides weight loss?

Table of Contents

Maven Consumer

Start GLP-1 with expert support by your side.

Maven specialists walk you through what to expect on GLP-1, including how to manage side effects and adjust your treatment if needed.

Start your assessment

Get GLP-1 care that accounts for all of you

Get started